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Abstract  
Elizabethkingia anophelis is an extensively antibiotic resistant emerging pathogen that 
causes mortality in the most vulnerable populations. Because of it’s high antibiotic 
resistance, there are very effective treatments for infections. The fluouroquinolone 
ciprofloxacin is an example of such treatment, which makes finding the cause of 
fluoroquinolone resistance in these organism of the upmost importance. Previous work in 
Gram-negative organisms, including E. anophelis, has shown that mutations in gyrA 
confers ciprofloxacin resistance. I hypothesized that laboratory-selected ciprofloxacin 
resistance in E. anophelis will result from mutation(s) in gyrA as well. To test this 
hypothesis, I isolated and sequenced five ciprofloxacin-resistant mutants of E, anophelis. 
All five strains exhibited increased ciprofloxacin minimal inhibitory concentrations 
(MICs) (8-16 mg/L) when compared to the parent strain (0.25 mg/L). After a population 
analysis, I found that each of the mutant strains had subpopulations the survived well 
beyond the normal MIC. Through DNA sequencing, I found eight unique and three 
shared mutations in gyrA, and no mutations in gyrB, parC, or parE. This demonstrated 
that even after a single exposure to ciprofloxacin, E. anophelis gyrA mutants emerged 
that were resistant to this drug.  
 
Introduction  
Elizabethkingia anophelis was first isolated from the midgut of the mosquito, 
Anopheles gambiae in 2011[1]. This bacterium is ubiquitous in nature and has been found 
in multiple countries and in multiple species[1-6]. E. anophelis mainly infects the 
immunocompromised, such as elderly or neonatal patients. The severity of this bacteria 
comes from it’s noticeable multiple-antibiotic resistance phenotype[4]. E. anophelis has 
shown resistance to ampicillin, cefotaxime, ceftazidime, imipenem, amikacin, 
gentamicin, kanamycin, strepytomycin, trobromycin, tetracycline, and 
chloramphenicol.[7] As a result of the multiple-antibiotic resistant phenotype, this 
bacterium is particularly difficult to treat and can have a mortality rate ranging from 
23.5%[8] -52%[9]. The aim of this study is to identify the gene mutation(s) that conferred 
ciprofloxacin-resistance in E. anophelis. Studying ciprofloxacin resistance in E. 
anophelis in the laboratory will provide insight into fluoroquinolone resistance in this 
newly emerging Gram-negative pathogen. Presently, ciprofloxacin resistance is very 
predominant in bacteria isolated from both hospitals[10] and healthy humans[11]. 
Understanding the mechanisms of antibiotic resistance in bacteria should allow us to find 
better therapeutic options for infections caused by resistant organisms.  
 
Elizabethkingia spp. 
 Elizabethkingia spp. are genetically diverse and gaining important traction in the 
research community. Elizabethkingia was initially classified as Flavobacterium[12]. 
Because of how broadly defined this genus was, it was reclassified into 
Chryseobacterium gen. nov in 1994[13]. In 2005, C. meningosepticum and C. miricola 
were found to be genetically heterogeneous from other Chryseobacterium species 
through 16S rRNA sequencing. Therefore, after combined phylogenetic and phenotypic 
anakyses, these two species were transferred to two new species within Elizavbethkingia: 
E. meningoseptica and E. miricola, respectively[14].. E. anophelis[1] was added to the 
species in 2011, and E. endophytica was later identified to be a sub-species of E. 
anophelis in 2016[15]. In 2017, Nicholson et al. proposed 3 more species, E. bruuniana, E.  
occulta, and E. ursingii [16].  
 
Ciprofloxacin 
Fluoroquinolones are one of the most used antibiotics on the market, mainly 
because of their broad spectrum of activity and excellent pharmacokinetic properties[17]. 
The parent compound of fluoroquinolones is nalidixic acid[18], which was first discovered 
in 1962 and shows antibacterial activity in a variety of disease-causing 
microorganisms[19]. Quinolone resistance develops by either a mutation in the genes 
encoding DNA gyrase and topoisomerase IV resulting in alterations of the drug’s target 
enzyme, or decreasing the concentration of the target within the cell[18]. The mutations of 
DNA gyrase are generally found in gyrA and gyrB, and the mutations of topoisomerase 
IV are generally found in parC, and parE[20]. Gram-negative resistance first occurs as an 
amino acid substitution in the quinolone-resistance-determining region (QRDR) of 
gyrA[21]. The QRDR of Escherichia coli occurs between positions 51 and 106, with 
specific mutations occurring at position 83 and 87 causing the greatest resistance[22].  
Mutations in genes controlling efflux pumps have also been shown to help reduce the 
internal concentration of quinolones[23].  Chakrabarty et al. showed that in 18 of their 
Enterobacteriaceae isolates, the presence of acrA, acrB, and tolC (genes that encode for 
the AcrAB-TolC efflux pump complex) were associated with increased fluoroquinolone 
resistance[24].  Additionally, plasmid-mediated quinolone resistance has begun to show 
increasing  prevalence among [Make Italics] Enterobacteriaceae[25]. qnr, the plasmid-
mediated resistance gene in E. coli, produces a protein that protect DNA gyrase from the 
quinolones[25]. Qnr protects DNA gyrase by reversing the gyrase-mediated DNA 
supercoiling caused by the quinolone, reducing gyrase binding to DNA, or by binding to 
gyrase directly to inhibit the gyrase-DNA interaction.  Currently, Elizabethkingia has not 
been shown to exhibit plasmid-mediated resistance, but the genome of this organism does 
encode a number of multi-drug efflux pumps[26].  
Ciprofloxacin is a second-generation fluoroquinolone that targets bacterial type II 
topoisomerases, enzymes which are essential during DNA replication[27]. Ciprofloxacin is 
effective against both Gram-negative and Gram-positive bacteria, and is used extensively 
in human and veterinary medicine[27]. Unfortunately, ciprofloxacin resistance is 
increasing in a multitude of medical cases, such as urinary tract infections[28] and E. coli 
infections[29]. In an in vitro study, Ghafur et al. (2013) found 29 E. meningoseptica 
isolates which were resistant to ciprofloxacin. These isolates were found in patients in a 
tertiary care oncology and stem cell transplant center that had received combination 
therapy with two or more antibiotics (cotrimoxazole, rifampicin, piperaillin-tazobactam, 
tigecycline, or cefepime-tazobactam). There was a 17% mortality rate among these 
patients[30]. Like other quinolones, conferred ciprofloxacin resistance is most likely 
attributed to mutations in gryA, gyrB, parC, and parE. Jorgensen et al. (2013 found 
nucleotide mutations in gyrA (T83I and D87Y) and gyrB (S465Y) in Pseudomonas 
aeruginosa strains with conferred ciprofloxacin resistance [31]. Dahiya et al. found 
mutations in gyrA gene (S83F and S83Y) and parC (S80I)  in Salmonella enterica 
serovar Typhi ciprofloxacin-resistant mutants[32]. This demonstrates that ciprofloxacin 
resistance is prevalent in an array of different Gram-negative bacteria, and that these 
mutations cluster around amino acid 83 in gyrA.  
 
E. anophelis + Ciprofloxacin  
Elizabethkingia spp. have commonly been treated with ciprofloxacin worldwide, with 
varying mortality rates (Table 1). In a recent E. anophelis outbreak in Wisconsin, Perrin 
et al. (2017) reported a low prevalence (9%) of ciprofloxacin resistance by Kirby-Bauer 
assay[8]. This contrasts Lin et al (2017)., who reported a much higher prevalence of 
resistance (78%) among strains isolated in Taiwan[2]. The results from these studies 
demonstrate that E. anophelis has the ability to develop ciprofloxacin resistance. While 
both of these studies reported mutations in gyrA, it is known that other genes are 
important for the development of ciprofloxacin resistance. However, what other 
mutations can lead to resistance, and where these mutations are, remains poorly 
understood.  
Therefore, the objective of this project was to obtain ciprofloxacin-resistant 
isolates of E. anophelis and to characterize mutations in regions that are known to be 
important to ciprofloxacin resistance.  Based on the literature, I hypothesized that E. 
anophelis ciprofloxacin resistance is likely to be associated with a mutation at position 83 
of DNA gyrase subunit A, in which serine is replaced by isoleucine[2, 8]. This study is of 
the upmost important because of the increasing prevalence of antibiotic-resistant strains 









E. meningoseptica  Vancomycin and ciprofloxacin  0/1  Brazil [34] 
E. meningoseptica  Ciprofloxacin and Imipenem-cilastatin  0/1 Taiwan [35] 
E. meningoseptica  Ciprofloxacin and piperacillin-tazobactam  0/1 Saudi Arabia 
[36] 
E. anophelis  Ciprofloxacin (4), vancomycin and ciprofloxacin (2), ciprofloxavin and 
trimethoprim/sulfamethoxazole (2), or ciprofloxacin and piperacillin/tazobactam (1)  
2/11 Wisconsin, 
USA [37] 
E. anophelis Ciprofloxacin (2/3) or Ampicillin-sulbactam then ciprofloxacin (1/3) 0/3 Hong Kong [5] 
E. anophelis  Penicillin G then cefuroxime and metronidazole then ciprofloxacin   0/1 Hong Kong [7] 
E. anophelis β-lactams (41.8%), β-lactam/Lactamase inhibitors (23.9%), levofloxacin (34.4%), 
ciprofloxacin (13.4%), carbapenems (16.4%), aminoglycosides (9%), tigecycline (9%), 
vancomycin (9%), and colistin (3%) 
 (19/67 total 
morbidity)a  
Taiwan [38] 
E. miricola Chloramphenicol and prednisolone, then ciprofloxacin  0/1 United 
Kingdom [39] 
E. miricola  Benzodiazepines, then imipenem-cilastatin and fluconazole, then ciprofloxacin with 
imipenem/cilastin, then ciprofloxacin with piperacillin/tazobactam 
0/1 Italy [40] 
E. miricola  Peicillin and dicloxacillin, then cefuroxime and ciprofloxacin, then piperacillin and 
tazobactam, then dicloxacillin and ciprofloxacin  
0/1 Denmark [41] 
C. 
meningosepticum 
Ciprofloxacin with no response after 6-7 days, switched to vancomycin and rifainpin 1/4 Turkey [42] 
a Mortality rate amongst cases treated with ciprofloxacin was not specified 





Working stocks and growth conditions 
Working stocks were maintained on heart infusion agar (HIA; Remel, Lenexa, KS) 
supplemented with 5% defibrinated rabbit blood (Hemostat, Dixon, CA). Overnight 
cultures were grown by inoculating 3 mL of Mueller Hinton broth (MHB; Becton 
Dickinson & Co, Cockeysville, MD) with a single isolated colony and incubated 
overnight with 200 rpm shaking at 37°C.   
 
Minimum inhibitory and bactericidal concentration assays 
Minimum inhibitory concentrations (MICs) and the minimal bactericidal concentrations 
(MBCs) were determined as previously described[26] using the broth microdilution 
procedure following standard CLSI[43] guidelines. Overnights were diluted to an optical 
density at 600nm (OD600nm) of 0.010 using MHB and 1 mL was added to 13 mm X 100 
mm screw top tubes containing two-fold serial dilutions of ciprofloxacin to yield final 
concentrations between 0.125 μg/ml and 128 μg/ml and incubated overnight at 37°C. 
MICs were recorded as the lowest concentration were no growth was observed. MBC 
was determined by plating 100 μl from each tube starting with the highest concentration 
of observable growth onto Mueller-Hinton agar (MHA) and incubated overnight at 37°C. 
The MBC was defined as the concentration of ciprofloxacin where no colonies were 
observed after incubation.  
 
Selection of Ciprofloxacin Mutants 
Mutants displaying reduced ciprofloxacin resistance were derived from E. anophelis 
OSUVM 1 by single step selection[26]. Briefly, overnight cultures were serially-diluted 
ten-fold in phosphate buffered saline and 100 μl of each dilution were spread onto MHA 
 
 
plates containing 0.5-2 X the observed MIC of ciprofloxacin and incubated for 48 hr at 
37°C. Colonies were counted and 5 isolated colonies were selected and passaged three 
times on drug-free MHA. The MICs for each colony was then determined as described 
above and  DNA was extracted from isolates demonstrating an increased ciprofloxacin 
MICs. DNA was isolated from 3 ml heart infusion broth (HIB) cultures of each isolate 
using Qiagen Genomic-tip 100/G columns (Qiagen, Hilden, Germany) following the 
manufacturers protocol.  
 
Sequencing 
gyrA, gyrB, parC, and parE genes were amplified using PCR and primers described in 
Table 2 and sequenced at the Oklahoma State University Core Facility using an ABI 
biosystems 3730 DNA sequencer following manufacturers recommendations. Resulting 
sequences were aligned to the OSUVM-1 parent strain wildtype gyrA, gyrB, parC, and 
parE genes, using the BLAST-N and BLAST-P algorithms [44, 45]. 
 
Table 2. Primers for Sanger sequencing of targeted genes. 
 
Primer Name Target Sequence 
EAgyrA-F gyrA CATGAAAGGTAACGCTAAGAACAC EAgyrA-R GCTCTTGTACAGAAGGCTCTAAC 
EAgyrB-F gyrB GGCCAGTAGTATTCAGTCGTTAG EAgyrB-R CCAGAATTTCTTCCGGTCTTCT 
EAparC-F parC ACCGGACAGACAGAACTTTATTC EAparC-R GTTGTGCCGCTTCTTGTTTG 
EAparE-F parE TTTCCTGCTGAGCCAACATAG EAparE-R TCCAGAAACCAGTCCTGATAAAG 
EAgyrACnf-F gyrA CGTCATTCTGCAAACCCTC EAgyrACnf-R TCATTTCTCCACCAGCATAATC 
EAgyrBCnf-F gyrB ATCGTTATTATGACCGATGCC EAgyrBCnf-R ACGCATCGCTACTTCTACC 









Overnights were serial diluted ten-fold in HIB and plated onto HIA infused with 
ciprofloxacin concentrations ranging from 0.25 μg/ml to 20 μg/ml. The plates were 




Selection of Ciprofloxacin Mutants 
Colonies were successfully isolated from all concentrations tested (Table 3). The five 
colonies selected for analysis demonstrated MIC’s that ranged from 8-16 mg/L. Mutation 












OSUVM-1 - - - 0.25 
OSUVM-CRS1 4 2 6.25 x 10-8 8 
OSUVM-CRS2 4 4 1.25 x 10-7 8 
OSUVM-CRS3 5 3 9.04 x 10-8 8 
OSUVM-CRS4 6 5 1.56 x10-7 16 




There were eight unique mutations, and three shared mutations (Table 4). All of the 
mutations were observed in the gyrA gene. OSUVM-CRS1 and OSUVM-CRS2 shared an 
amino acid mutation at K297R and V301L. OSUVM-CRS3 and OSUVM-CRS4 shared 
an amino acid mutation at V158E. OSUVM-CRS3 and OSUVM-CRS5 had a shared 
amino acid mutation at R162K (Table 3). OSUVM-CRS1 had a unique amino acid 
Table 3. Ciprofloxacin MICs 
 
 
Table 4. Nucleotide and amino acid mutations from reduced susceptibility mutants.  
mutation at I301M and E304D. OSUVM-CRS3 had a unique amino acid mutation at 
Q146L (Table 4).  
 
Isolate Gene Nucleotide Mutations Amino Acid Mutations 
OSUVM-CRS1 gyrA A890G; T903G; G904C; 
A912C 
K297R; I301M; V302L; E304D 
OSUVM-CRS2 gyrA A890G; G904C K297R; V302L 
OSUVM-CRS3 gyrA G485A; T473A; A437T R162K; V158E; Q146L 
OSUVM-CRS4 gyrA T473A V158E 
OSUVM-CRS5 gyrA G485A R162K 
 
Population Analysis 
OSUVM 1 had a large drop in population at 0.25 mg/L, whereas the five mutants showed 
decreases at higher concentrations (Figure 1). OSUVM-CRS1 did not have a clear break 
point, but started decreasing at 4 mg/L. OSUVM-CRS2 had a break point at 4 mg/L. 
OSUVM-CRS3 had a break point at 1 mg/L. OSUMV-CRS4 had a break point at 12 
mg/L. OSUVM-CRS5 had a break point at 12 mg/L. OSUVM-CRS5 did not demonstrate 
a notable decrease in survival until ~12 mg/L. All of the mutant strains showed survival 
even at 20 mg/L, while no surviving colonies were detecting for the parent strain above 4 
mg/L (Figure 1). 
 
 
Figure 1. Ciprofloxacin resistance population analysis. OSUVM1 is our parent strain of E. anophelis. OSUVM-CRS1-5 are our ciprofloxacin-resistant 




Discussion   
Selection of Ciprofloxacin Mutants 
I successfully selected, isolated, and characterized mutants of E. anophelis with reduced 
susceptibility to ciprofloxacin (Table 3). The MIC of these mutants were increased when 
compared to the parent strain. OSUVM-CRS1, OSUVM-CRS2, and OSUVM-CRS3 had 
MICs of 8 mg/L, a 32-fold increase from the parent strain. OSUVM-CRS4 and OSUVM-
CRS5 had MICs of 16 mg/L, a 64-fold increase from the parent strain. Han et al. (2017) 
found ciprofloxacin MICs ranging from 1 to >64 by agar dilution in their 51 E. anophelis 
isolated. They found that 22% of the isolates were susceptible, 6% had intermediate 
susceptibility, and 72% were resistant to ciprofloxacin as interpreted by the CLSI non-
Enterobactericiae standards[46]. Comparatively, Lin et al. (2018) found that their 67 E. 
anophelis isolates showed ciprofloxacin MICs between <1 mg/L and >32 mg/L. Four 
point five % of the isolates were susceptible, 50.7% had intermediate susceptibility, and 
44.8% were resistant to ciprofloxacin by microtiter interpreted according to the non-
Enterobactericiae breakpoints established by the CLSI. This is a fairly large frequency, 
especially since only 13.4% of the patients were empirically treated with ciprofloxacin 
[38]. Both of these reports compare with my recorded MIC values for my ciprofloxacin-
resistant mutants. While Perrin et al. reported high rates of susceptibility (89.7% 
susceptible, 6.9% intermediate susceptibility, and 3.4% resistant), they used the Kirby 
Bauer disk diffusion method interpreted using EUCAST breakpoints for Pseudomonas 
spp., and therefore direct comparison is not acceptable. I only found a few ciprofloxacin-
resistant mutants, as expected given the low mutation rates ranging from 1.25 x 10-7 to 
9.04 x 10-8 (Table 3). However, a single step selection procedure was used to select for 
 
 
mutants. This demonstrates that even a single exposure to ciprofloxacin can select for 
mutants demonstrating elevated resistance to ciprofloxacin, albeit at a low frequency.  
 
Sequencing 
Mutations in gyrA were found to cause alteration in GyrA at amino acid residues 
146, 158, 162, 297, 301, 302, and 304 (Table 4). Contrary to previous reports[2, 8, 38], I 
found no mutation at amino acid position 83. This shows that a mutation at this position 
is common but not necessary for conferred ciprofloxacin resistance. No mutations were 
found in gyrB, parC, or parE. The lack of mutations in these genes is consistent with all 
previously reported sequencing of ciprofloxacin-resistant mutants[2, 8, 38].  
To date, there is no known characterized QRDR for E. anophelis. The QRDR of 
E. coli is between positions 51 and 106 of gyrA[47]. Additionally, mutations that also 
confer ciprofloxacin resistance in E. coli are commonly found in amino acid positions 
426 and 447 of GyrB, 78, 80, and 84 of ParC, or 445 of ParE[47]. Some of the mutations 
are close to the known QRDR of E. coli (positions 146, 158, and 162) but some are not. 
Mutations at amino acid position 297, 301, and 304 were not close to the known QRDR. 
 
Population Analysis 
After a single exposure to ciprofloxacin, I found subpopulations of both the parent strain 
and the mutant strains that survived past the recorded MICs (Fig. 1). OSUVM-CRS5 
consistently had the largest number of CFU/mL until the final concentration, in which 
OSUVM-CRS1 had the highest CFU/mL (Fig. 1). This poses concern for treatment, 
because even after one exposure of ciprofloxacin, resistant subpopulations arose. This 
can cause complications because ciprofloxacin is commonly used to treat E. anophelis 
 
 
(Table 1). Moreover, Lin et al. (2018) showed rapid emergence of resistance in a large 
number of isolates. Subpopulations of ciprofloxacin-resistant mutants also commonly 
appear in in both E. coli[48] and P. aeruginosa[49]. Olofsson et al. (2006) found several E. 
coli subpopulations showing varying levels of ciprofloxacin resistance while evaluating 
mutant prevention concentration of 3 ciprofloxacin reduced susceptibility strains[48]. 
Similar results were observed by Hansen et al. (2006) who exposed 6 strains of P. 
aeruginosa to varying concentrations of ciprofloxacin or levofloxacin, observing that the 
fraction of colonies recovered compared to the input number of colonies decreased 
sharply near the MIC, although colonies continued to be recovered at concentrations up 
to five times the MIC[50]. Furthermore, mutants displaying elevated ciprofloxacin 
resistance were selected from these plates displaying mutations in gyrA only. I observed 
similar results with both the parent and mutant strains, all of which displayed 
subpopulations that survived well past the nominal MIC.  
 
Conclusion and future directions 
I have found that ciprofloxacin-resistance can emerge rapidly in E. anophelis after a 
single exposure to the drug. In contrast to the original hypothesis, no mutations were 
found that affected amino acid position 83. While a mutation that confers increased 
ciprofloxacin resistance is frequently found in position 83 of gyrA[8, 38], I found that this is 
not the only position where a mutation can confer increased resistance, raising the 
possibility that the QRDR for Elizabethkingia covers a larger portion of the protein than 
those in other organisms. Moreover, it seems that mutations are most likely to occur in 
the gyrA gene, as I found no other mutations in gyrB, parC, or parE. There are some 
possible confounding variables in this study. Only a small number of isolates were 
 
 
sequenced, and the selection of those isolates was done in vitro. I did not look for 
mutations that suggested an increase in efflux pump activity. While the OSUMV-1 
genome did show efflux pumps, whether those were drug-resistance efflux pumps is still 
to be determined. Additionally, plasmid-mediated resistance is unlikely because 
OSUVM-1 did not show any qnr genes, nor were any sequences related to known 
plasmids detected[26].  Whole genome sequencing will be required to identify any 
additional mutations that are contributing to the multiple-antibiotic resistance phenotype 
selected by ciprofloxacin exposure. Since E. anophelis has rapidly emerging worldwide 
significance, I hope that these findings help to spark further research into E. anophelis 
antibiotic resistance mechanisms, which hopefully can lead to more effective treatments 
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